Research On Patent Strategy Model Of Demestic Pharmaceutical Enterprise

In the developed countries, the pharmaceutical industry has always been the relatively perfect protected in the intellectual property rights industry, European and American multinational pharmaceutical groups have strong awareness of the patent protection, and the results of acquisition are significantly. As a result, many multinational companies have upgraded their patent to a powerful strategic weapons, aim to motivate their own R&D, raise the market sales, expand the market share, and hold back the competitors, so as to monopoly the market and achieve the final profits. While the domestic pharmaceutical enterprises has the week awareness of the patent protection for a long time, and has a insufficient understanding on its significance to the enterprise competition.With China's accession to the WTO, the domestic pharmaceutical enterprise exposed to multinational pharmaceutical giant in direct competition more and more frequently, and frequently prosecuted for patent right, the situation of which through the overflowing of me-too drugs from abroad, and the cost advantages to compete with the foreign pharmaceutical enterprise has broken. The only way to survive is to learn from foreign pharmaceutical enterprises, and focus on the construction of the patent protection mechanism, so as to build the own competitiveness under the new circumstances. As a result, study and analyze the patent competition environment together with its construct patent strategy of foreign pharmaceutical enterprise has become very important.This article study and analyze the implementation of domestic and foreign pharmaceutical enterprise patent strategy, classify and sum up the existent four kind of typical patent strategy model, and through the domestic listing pharmaceutical company—HuaDong medicine's patent strategy to verify it! Concluded: domestic pharmaceutical enterprises in this particular circumstances, enterprises should under the case of make full use of the national policy, make more efforts in terms of system completion, structure three-dimension and the whole process of the patent protection, meanwhile, the upgrade of the level of patent strategy is also a striving direction of the domestic pharmaceutical enterprises.